This is the major route of elimination of HNE and other electrophiles that conjugate with GSH
Comme le montrent les quelques tudes slectionnes en fin darticle, un faible taux de GSH est observ dans de nombreuses pathologies dgnratives chroniques , telles que : Troubles neurodgnratifs (Alzheimer, Parkinson, maladie de Huntington, maladie de Charcot ou Sclrose Latrale Amyotrophique SLA , maladie de Friedreich, autisme) Maladie pulmonaire (Maladie Pulmonaire Obstructive Chronique, asthme et syndrome de dtresse respiratoire aigu) Maladies immunitaires (VIH, maladies auto-immunes) Maladies cardiovasculaires (hypertension, infarctus du myocarde, oxydation du cholestrol) Maladies chroniques lies lge (cataractes, dgnrescence maculaire, glaucome et dficience auditive) Maladies du foie Fibrose kystique Processus de vieillissement en gnral
Eprenetapopt is converted to the Michael acceptor methylene quinuclidinone (MQ), which inhibits the antioxidant metabolite GSH (glutathione) by reacting with its thiol groups 14
(81) hydrolysed quinoa protein using food-grade enzymes, identified 136 peptides, 35 of which were predicted as potentially bioactive peptides (BAPs) based on the Peptide Ranker score, and have high potential for inhibition of DPP-IV, AG, and ACE, DPP-IV inhibition is a key target in the treatment of T2DM, and DPP-IV inhibitors were among the first oral hypoglycaemic agents prospectively designed as glucose-lowering agents
